LaBarre Michael J. 4
4 · HALOZYME THERAPEUTICS, INC. · Filed Feb 27, 2025
Insider Transaction Report
Form 4
LaBarre Michael J.
VP, Product Development
Transactions
- Sale
Common Stock
2025-02-26$58.09/sh−9,400$546,055→ 176,053 total - Sale
Common Stock
2025-02-27$58.74/sh−100$5,874→ 173,756 total - Sale
Common Stock
2025-02-25$58.67/sh−700$41,069→ 185,453 total - Sale
Common Stock
2025-02-25$58.01/sh−9,300$539,465→ 186,153 total - Sale
Common Stock
2025-02-26$58.65/sh−600$35,189→ 175,453 total - Sale
Common Stock
2025-02-27$58.25/sh−1,597$93,028→ 173,856 total
Footnotes (6)
- [F1]The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.
- [F2]Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F4]Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F5]Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F6]Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.